Prescription medicine

Glycopyrronium Brand names: Qbrexza

Glycopyrronium (Qbrexza) is a prescription medicine with an FDA approval on record since 2018. No generic is listed in FDA's NDC Directory.

No generic listed

Check it at the source: the glycopyrronium FDA label on DailyMed (effective May 21, 2026, Journey Medical Corporation); the NDA 210361 record on Drugs@FDA; every glycopyrronium label on DailyMed.

Highlights of the record

FDA label of May 21, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

From the label: indications and usage
Qbrexza is indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.

Forms and strengths

2.4 g/100g

Cloth.

On the market

Earliest approval on file: June 28, 2018 Qbrexza, Journey; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals: 1 first April 3, 2026; 0 with a marketed status in Drugs@FDA
Labelers listed (NDC): 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Last listed patent: February 28, 2033 Qbrexza cloth; not a generic launch date

Supply and safety

Pharmacy cost (NADAC): Not in the survey
Shortage (FDA): No current entry
Recalls by its makers (FDA): No recall recorded
FAERS reports: 1,514 through July 30, 2026

What is glycopyrronium used for?

From the label: indications and usage
Qbrexza is indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older ( 1 ).

FDA pharmacologic class: Anticholinergic and Cholinergic Muscarinic Antagonist.

Source: FDA drug label (Qbrexza), Journey Medical Corporation, effective May 21, 2026 (SPL set 5b372650-e56e-47a5-93e2-c0c292017059), via openFDA; the full label on DailyMed

What does the patient leaflet for glycopyrronium say first?

The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.

From the patient leaflet: What should I avoid while using Qbrexza?
Avoid touching eyes. Qbrexza may cause you to have blurred vision that is temporary. If you develop blurred vision, call your healthcare provider, stop using Qbrexza and do not drive, operate machinery, or do hazardous work until your vision is clear. Qbrexza is flammable. Avoid heat and flame while applying Qbrexza to your skin.

From the patient leaflet: How should I store Qbrexza?
Store Qbrexza at room temperature between 68°F and 77°F (20°C and 25°C). Qbrexza is flammable. Keep Qbrexza away from heat and flame. Keep Qbrexza and all medicines out of the reach of children.

Source: FDA drug label (Qbrexza), Journey Medical Corporation, effective May 21, 2026 (SPL set 5b372650-e56e-47a5-93e2-c0c292017059), via openFDA; the full label on DailyMed

Is there a generic for glycopyrronium (Qbrexza)?

The FDA approved the first generic glycopyrronium on April 3, 2026. 1 generic application is approved; 0 of it carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.

The Orange Book lists 8 patents for Qbrexza cloth: the compound patent runs to February 28, 2033. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

2018 earliest approval on file
2026 first generic approved
2033 last listed patent

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What do FAERS reports show for glycopyrronium?

The FDA Adverse Event Reporting System holds 1,514 reports that list glycopyrronium among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 94 are coded as a death and 406 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

Reports received each year

The most reported reactions

Mydriasis (named in the label)271
Dry Mouth (named in the label)236
Off Label Use (a use or a product term, not a reaction)194
Vision Blurred (named in the label)184
Drug Ineffective (a use or a product term, not a reaction)94
Intentional Product Misuse (a use or a product term, not a reaction)94
Urinary Retention (named in the label)85
Headache (named in the label)84

Side effects: the label's list and every FAERS reaction

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What next?

Other anticholinergics: the pharmacologic class, with prices and generics
Glycopyrronium side effects: the label's list beside FAERS reports
Check an interaction: what two or more labels say about each other